Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women

To prevent the global health burdens of human immunodeficiency virus [HIV] and unintended/mistimed pregnancies, we developed an intravaginal ring [IVR] that delivers tenofovir [TFV] at ~10mg/day alone or with levonorgestrel [LNG] at ~20μg/day for 90 days. We present safety, pharmacokinetics, pharmac...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Thurman, Andrea Ries, Schwartz, Jill L., Brache, Vivian, Clark, Meredith R., McCormick, Timothy, Chandra, Neelima, Marzinke, Mark A., Stanczyk, Frank Z., Dezzutti, Charlene S., Hillier, Sharon L., Herold, Betsy C., Fichorova, Raina, Asin, Susana N., Rollenhagen, Christiane, Weiner, Debra, Kiser, Patrick, Doncel, Gustavo F.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2018
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6023238/
https://ncbi.nlm.nih.gov/pubmed/29953547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0199778
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki